Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.32 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.32 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 2/20 | 0.31 |
| ▸ | MMP9 | P14780 | 2/20 | 0.31 |
| ▸ | MMP13 | P45452 | 2/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.31 |
| ▸ | EDNRB | P24530 | 1/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4709531 | 0.84 | CYP3A4 (0.35) | CYP3A4LMNATP53MAPTNR1H2 | |
| SCHEMBL4095782 | 0.76 | NR1H2 (0.34) | LMNANR1H2NR1H3RORC | |
| SCHEMBL4090468 | 0.65 | MAPT (0.39) | LMNATP53MAPTNPBWR1 | |
| SCHEMBL4095980 | 0.64 | PTGDR (0.33) | CYP3A4LMNATP53MAPTNPBWR1 | |
| SCHEMBL4105507 | 0.61 | GRIN1 (0.42) | MAPTNPBWR1GPBAR1AKR1C3AKR1C2 | |
| SCHEMBL4102486 | 0.60 | MAPT (0.34) | CYP3A4LMNATP53MAPT | |
| SCHEMBL4095773 | 0.58 | PDE2A (0.38) | CYP3A4RORC | |
| SCHEMBL4095778 | 0.58 | CRHR1 (0.36) | RORC | |
| SCHEMBL4096314 | 0.57 | GSK3A (0.38) | LMNAMAPT | |
| SCHEMBL4106287 | 0.55 | SMN1; SMN2 (0.35) | CYP3A4LMNAMAPTGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1903045-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MC2R, CRHR1, AVPR2 | CYP3A4 372/4885LMNA 4743/4885TP53 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.